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Abstract
Mammalian microRNA expression is dysregulated in human cancer. However, the func-
tional relevance of many microRNAs in the context of tumor biology remains unclear. Using
CRISPR-Cas9 technology, we performed a global loss-of-function screen to simultaneously
test the functions of individual microRNAs and protein-coding genes during the growth of a
myeloid leukemia cell line. This approach identified evolutionarily conserved human micro-
RNAs that suppress or promote cell growth, revealing that microRNAs are extensively inte-
grated into the molecular networks that control tumor cell physiology. miR-155 was
identified as a top microRNA candidate promoting cellular fitness, which we confirmed with
two distinct miR-155-targeting CRISPR-Cas9 lentiviral constructs. Further, we performed
anti-correlation functional profiling to predict relevant microRNA-tumor suppressor gene or
microRNA-oncogene interactions in these cells. This analysis identified miR-150 targeting
of p53, a connection that was experimentally validated. Taken together, our study describes
a powerful genetic approach by which the function of individual microRNAs can be
assessed on a global level, and its use will rapidly advance our understanding of how micro-
RNAs contribute to human disease.
Introduction
Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy that carries a poor
prognosis. In AML, hematopoiesis is disrupted by the overproduction of transformed myeloid
cells, leading to life-threating anemia, immunosuppression, and bleeding due to decreased nor-
mal blood cell production. A variety of genetic and epigenetic aberrations are thought to drive
leukemic phenotypes, including alterations in protein-coding genes and microRNAs.
MicroRNAs (miRNAs) are small non-coding RNAs that repress their target genes by bind-
ing to cognate 3’ UTR sites in their respective mRNA targets, preventing their translation and/
or triggering mRNA degradation. miRNA expression is highly dysregulated in AML [1, 2], and
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certain miRNAs have been shown to modulate leukemia cell biology in vitro [3]. Furthermore,
the overexpression of a few specific miRNAs is sufficient to induce leukemic transformation in
mice [4, 5], whereas other miRNAs act as tumor suppressors via repression of known protein
oncogenes in hematopoietic malignancy [6, 7]. However, while the dysregulation of a number
of miRNAs has been implicated in leukemia, the functional impact of many miRNAs and their
putative targets on leukemic phenotypes remains unclear.
In this study, we took an unbiased, global loss-of-function approach to determine which
miRNAs, and which of their putative targets, are involved in MV4-11 cell line growth, a model
of myeloid leukemia. Because of the many caveats associated with previously described meth-
ods of miRNA loss-of-function screening that limits their use, we employed CRISPR-Cas9
technology [8–10]. Using this approach, each human miRNA and protein-coding gene in
MV4-11 cells was individually disrupted and the impact on cellular growth was determined.
Results point to a subset of evolutionarily conserved miRNAs that regulate cellular growth, and
have also determined the impact of predicted miRNA targets that mediate these effects on
tumor cell proliferation and survival. Furthermore, we have validated miR-150 as a critical pro-
moter of leukemic cell growth in our system through targeting of p53. Taken together, our
study demonstrates that CRISPR-Cas9 technology can be used to identify novel, functionally
relevant miRNAs in mammalian cell phenotypes, while simultaneously identifying putative
target proteins with opposing function. Our dataset also provides a resource describing the
effects of individual miRNAs and protein-coding genes on leukemic cell fitness.
Results
CRISPR-Cas9 screen identifies protein-coding genes that regulate AML
cell line growth
In order to determine which protein-coding genes and miRNAs regulate leukemic cell growth,
we utilized a genome-scale CRISPR-Cas9 library (lentiCRISPRv2 library) [11, 12] to disrupt
specific genes and evaluate the impact on cellular fitness over time. The lentiCRISPRv2 library
contained 3 unique single guide RNAs (sgRNAs) targeting each protein-coding gene, as well as
4 unique sgRNAs targeting each miRNA gene locus cloned into an all-in-one CRISPR-Cas9
construct (lentiCRISPRv2). MV4-11 cells, a human-derived AML cell line homozygous for the
FLT3-ITD mutation [13] and positive for the fusion protein MLL-AF4 [14], were transduced
with the lentiCRISPRv2 library at ~250X coverage and an MOI of 0.3 to favor single viral inte-
grations. An initial time point (TP0) was taken two days post-infection to assess library repre-
sentation. Cells were selected with puromycin (puro) for 7 days, at which point puro was
removed and growth was allowed to continue for an additional 16 days before a final time
point (TP23) was collected (Fig 1A). Following genomic DNA (gDNA) extraction from cells at
both time points and PCR amplification of each sgRNA sequence, we performed Illumina
sequencing to generate read counts for each gene-targeting lentiCRISPRv2 construct. In order
to accurately determine the impact of each gene on cell fitness over the 23-day time course, we
combined the normalized read counts of all lentiCRISPRv2 constructs targeting a given gene at
TP23 and expressed this as log2 fold change relative to the initial abundance of constructs at
TP0 using DEseq2. We calculated the average log2 fold change across three independently-per-
formed experiments to determine whether loss-of-function of each gene expressed in MV4-11
cells led to increased, decreased, or no change in cell growth over time using a cutoff p-value of
0.05. Furthermore, MV4-11 cells were transcriptionally profiled using RNA sequencing, and
only expressed genes were included in our analysis. Using this approach, we identified protein-
coding genes whose deletion significantly affected MV4-11 cell growth (Fig 1B and S1 Table).
Of the 19,052 protein-coding genes targeted in our screen, we found 715 genes whose deletion
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Fig 1. CRISPR-Cas9 loss-of-function screen identifies protein-coding genes, including known oncogenes STAT5A and BCL2, as important for
MV4-11 cell line growth. (A) Overall experimental design of lentiCRISPRv2 library screen. (B) Log2 Fold Change of each protein-coding gene targeted in
lentiCRISPRv2 library screen (x-axis) plotted against–Log10 P-Value (y-axis). Dotted line represents p-value = 0.05. (C) Fold change of STAT5A normalized
read counts in lentiCRISPRv2 library screen as compared to TP0. (D) Western blot of STAT5A using cellular extract from STAT5A-CR1, STAT5A-C2, or EV
MicroRNA CRISPR-Cas9 Screen in Myeloid Leukemia Cells
PLOS ONE | DOI:10.1371/journal.pone.0153689 April 15, 2016 3 / 11
consistently resulted in increased cell numbers, which included many known tumor suppressor
genes (TSGs). We also identified 516 genes whose deletion reproducibly resulted in decreased
cellular growth, including a number of known oncogenes.
Signal transducer and activator of transcription 5A (STAT5A) was among the known onco-
genes that our screen identified as important for cell growth (Fig 1B and 1C). STAT5 is a key
signaling pathway that is inappropriately activated by FLT3-ITD mutations [15] and promotes
FLT3-ITD driven growth. Thus, we tested the efficacy of two distinct STAT5A targeting lenti-
CRISPRv2 constructs (STAT5A-CR1 and STAT5A-CR2) through individual transduction of
MV4-11 cells, and observed significantly reduced STAT5A protein levels by western blotting
two weeks post-infection (Fig 1D). We sequenced the STAT5A locus in individual clones trans-
duced with the STAT5A-CR1 vector and found that 80% of cells contained mutations at the
expected Cas9 cut site (Fig 1E). STAT5A-CR1 and STAT5A-CR2 cells grew at a slower rate
than cells transduced with a lentiCRISPRv2 empty vector (EV) control, confirming results
from our screen indicating that STAT5A is a promoter of FLT3-ITD+ leukemic cell growth
(Fig 1F and 1G). Similar results were obtained when we independently validated another
known oncogene, BCL2 (Fig 1H–1J).
Interestingly, we also found that cells with CRISPR-Cas9-mediated depletion of Argonaute
2 (Ago2), Dicer, or Drosha, important proteins in the miRNA processing pathway, displayed
reduced cell numbers over time, with p-values that trended towards, but did not reach, statisti-
cal significance (Data not shown). Because these genes are all in the miRNA biogenesis path-
way, we sought to investigate this observation further. Therefore, we created Ago2 (Ago2-CR1)
and Drosha (Drosha-CR1) deleted MV4-11 cell lines by using the lentiCRISPRv2 system to
deliver sgRNAs against each of these protein-coding genes, and deletion was confirmed via
western blotting (Fig 2A). These cell lines also demonstrated decreased cellular growth com-
pared to EV-infected control MV4-11 cells (Fig 2B), suggesting that microRNAs were playing
a net role in promoting cell growth in this context.
Critical role for specific, evolutionarily conserved miRNAs during MV4-
11 cell growth
We next evaluated which individual miRNAs were playing a functional role in regulating
MV4-11 cell growth. We found that 27 of the 197 evolutionarily conserved miRNAs targeted
in our screen had a positive or negative influence on cell numbers over time with an average
fold change p-value of less than 0.05 when the 3 biological replicate experiments were com-
bined (Fig 2C and S2 Table). Only mature miRNAs expressed in MV4-11 cells, as assessed by
RNA sequencing, were considered in our analysis. Interestingly, we found that fewer miRNAs
had a functional effect during our screen than protein-coding genes. This observation could be
explained by the fact that there are fewer miRNA vs protein-coding genes overall. Furthermore,
this finding may also be due to the observation that miRNAs typically display only partial
repression of their mRNA targets leading to modest changes in protein levels, whereas many
protein-coding genes encode essential proteins that regulate core cellular processes required
for growth and viability. miR-150, miR-155, and miR-182 were included in our top hits among
control infected MV4-11 cells with actin serving as load control. (E) DNA sequencing of the STAT5A locus from four representative STAT5A-CR1 infected
MV4-11 clones (C1-C4). STAT5A represents the wild type (WT) sequence. Black box indicates translational start site. Arrow represents predicted cleavage
site of Cas9 endonuclease. Red box identifies mutated region, with dashed lines indicating deleted nucleotides. (F, G) Growth curve for STAT5A-CR1 or
STAT5A-CR2 infected MV4-11 cells compared to EV control. (H) Fold change of BCL2 normalized read counts in lentiCRISPRv2 library screen as compared
to TP0. (I) Western blot of BCL2 in BCL2-CR1 or EV control infected MV4-11 cells with actin serving as load control. (J) Growth curve for BCL2-CR1 infected
MV4-11 cells compared to EV control. (B, C, H) Represents combined data from three independently performed lentiCRISPRv2 library infections. Data
represented as mean +/- SEM. P-values as indicated: *0.05, **0.01, ***0.001, and ns p>0.05. See also S1 Table.
doi:10.1371/journal.pone.0153689.g001
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Fig 2. Identification of individual microRNAs, includingmiR-155, that regulate MV4-11 cell line growth. (A) Western blots of Ago2 and Drosha using
cellular extract from Ago2-CR1, Drosha-CR1, and EV infected MV4-11 cell lines with actin serving as load control. (B) Growth curve for Ago2-CR1 and
Drosha-CR1 infected MV4-11 cells compared to EV control. (C) Log2 Fold Change of each conserved microRNA gene targeted in lentiCRISPRv2 library
screen (x-axis) plotted against–Log10 P-Value (y-axis). Dotted line represents p-value = 0.05. Represents combined data from three independently
performed lentiCRISPRv2 library infections. (D) Schematic of miR-155 hairpin sequence as annotated in miRBase and sgRNA design of two independent
miR-155-targeting lentiCRISPRv2 constructs (155-CR1, 155-CR2). (E) Expression levels of miR-155 in MV4-11 cells infected with EV control, 155-CR1, or
155-CR2 lentiCRISPRv2 constructs determined by qPCR. Expression normalized to 5s. (F) DNA sequencing of five representative 155-CR1 and 155-CR2
infected MV4-11 clones (C1-C5). 155 represents the WT sequence. Arrow indicates predicted cleavage site of Cas9. Red box identifies the mutated region,
with dashed lines indicating deleted nucleotides. (G) Competitive growth curve of EV (GFP+), 155-CR1 (GFP+), or 155-CR2 (GFP+) infected MV4-11 cells
mixed ~1:1 with WTMV4-11 cells at time point 0. Y-axis = (%GFP+ cells at indicated time point)/(%GFP+ cells initial). Data represented as mean +/- SEM. P-
values as indicated: *0.05, **0.01, ***0.001, and ns p>0.05. See also S2 Table.
doi:10.1371/journal.pone.0153689.g002
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conserved miRNAs that promote cell growth. Of relevance, all three have previously been
implicated in hematopoietic malignancy [16–18]. We also identified conserved miRNAs that
acted to repress cell growth in our screen, including miR-491 and miR-335.
miR-155 was identified as a top miRNA candidate that promoted FLT3-ITD+ cell growth
(Fig 2C). Interestingly, miR-155 is also the most highly dysregulated miRNA in primary
FLT3-ITD+ AML cells compared to FLT3-WT AML or normal CD34+ hematopoietic stem
and progenitor cells [1, 2], and has been implicated in regulating the survival and growth of
FLT3-ITD+ cells [19]. To independently validate miR-155, we used two distinct lentiCRISPRv2
constructs represented in our library to generate miR-155 deficient FLT3-ITD+ cell lines; one
targeting the mature miRNA region of the miR-155 hairpin sequence (155-CR1), and the other
targeting the loop (155-CR2) (Fig 2D). We found that cell lines carrying the 155-CR1 or
155-CR2 constructs had significantly decreased levels of mature miR-155 (Fig 2E). We further
analyzed the mutations being created by 155-CR1 and 155-CR2, and found that 15/16 clones
analyzed (8/8 of 155-CR1; 7/8 of 155-CR2) contained mutations at the predicted Cas9 cut site
(Fig 2F). Of these 15 mutations, we observed 12 deletions and 3 insertions, indicating that
NHEJ-mediated deletions were favored in these cells. 5 of the 7 clones analyzed that had been
transduced with 155-CR1 contained mutations spanning the seed sequence, the critical portion
of the mature miRNA that leads to target repression via complementary binding to the 3’ UTR.
In the case of 155-CR2, we conclude that deletion of the loop region leads to disrupted biogene-
sis of mature miR-155. Both 155-CR1 and 155-CR2 cells exhibited decreased competitive cell
growth compared to EV control cells (Fig 2G), thus confirming our library findings.
Anti-correlation functional profiling identifies relevant microRNA-target
pairs, including miR-150 and p53
We also used our dataset to identify miRNAs predicted to target known oncogenes and TSGs
(S3 Table). In the case of several representative oncogenes, their promotion of cell growth
inversely correlated with the impact of specific miRNAs with conserved binding sites in their 3’
UTRs (Fig 3A). Similar observations were made for a subset of known TSGs, where their nega-
tive effects on cell growth inversely correlated with the impact of specific miRNAs with con-
served binding sites in their 3’UTRs (Fig 3B). This approach, which we refer to as anti-
correlation functional profiling, is a powerful method that can be used to globally identify
miRNA-target gene pairs that may be functionally linked.
To test the ability of anti-correlation functional profiling to identify functionally relevant
miRNA-target pairs in our system, we tested the top association from our miRNA-TSG plot,
TP53 (p53) and miR-150. miR-150, the top miRNA hit in our lentiCRISPRv2 library screen,
has a conserved binding sequence in the 3’UTR of p53 (Fig 3C), and has been shown to be
directly targeted by miR-150 in luciferase reporter assays [20, 21]. We generated a lenti-
CRISPRv2 construct designed to cut near the mature miRNA coding sequence using one of the
miR-150 sgRNAs (150-CR1) represented in the lentiCRISPRv2 library (Fig 3D), and confirmed
that 150-CR1 containing MV4-11 cells displayed a significant decrease in miR-150 levels com-
pared to EV control cells by qPCR (Fig 3E). We also generated p53 deficient cell lines
(p53-CR1), again using a sgRNA from the lentiCRISPRv2 library cloned into a lentiCRISPRv2
construct. We confirmed that p53 protein levels were reduced in the p53-CR1 cells compared
to EV control cells (Fig 3F), and saw an increase in p53 protein level in the 150-CR1 cells com-
pared to EV control, indicating that miR-150 is indeed repressing p53 in MV4-11 cells. Finally,
we observed that p53-CR1 cells had a competitive growth advantage compared to EV infected
cells (Fig 3G), while 150-CR1 cells had a growth disadvantage. These results validate our anti-
correlation functional profiling approach to finding relevant miRNA-target pairs that regulate
MicroRNA CRISPR-Cas9 Screen in Myeloid Leukemia Cells
PLOS ONE | DOI:10.1371/journal.pone.0153689 April 15, 2016 6 / 11
specific cellular phenotypes, and point to miR-150 repression of p53 as a significant pro-
growth and survival mechanism in at least some types of myeloid leukemias.
Fig 3. Anti-correlation functional profiling identifies relevant miRNA-target interactions, includingmiR-150 repression of p53, that regulate MV4-11
cell line growth. (A) Heat map indicating representative oncogenes whose loss leads to decreased cell growth according to Log2 Fold Change values from
lentiCRISPRv2 library screen (first column), and functionally anti-correlated miRNAs that are predicted to target each oncogene. Grey boxes indicate that the
miRNA is not predicted to bind the 3’UTR of the oncogene (NT = Not targeted). (B) Heat map indicating representative TSGs whose loss lead to increased
cell growth according to our Log2 Fold Change values from lentiCRISPRv2 library screen (first column), and miRNAs predicted to target each TSG whose
growth anti-correlated in library. Grey boxes indicates that the miRNA is not predicted to bind the 3’UTR of TSG (NT = Not targeted). (C) Schematic showing
miR-150 targeting of the p53 3’UTR. (D) Schematic of the miR-150 hairpin sequence as annotated in miRBase and sgRNA design of the miR-150-targeting
lentiCRISPRv2 construct (150-CR1). (E) Expression level of miR-150 in MV4-11 cells infected with EV control or 150-CR1 lentiCRISPRv2 constructs
determined by qPCR. Expression normalized to 5s. (F) Western blot of p53 in p53-CR1, 150-CR1, and EV control infected MV4-11 cell lines with actin
serving as load control. (G) Competitive growth curve of EV (GFP+), p53-CR1 (GFP+), or 150-CR1 (GFP+) infected MV4-11 cells mixed ~1:1 with WTMV4-
11 cells at time point 0. Y-axis = (%GFP+ cells at indicated time point)/(%GFP+ cells initial). (A, B) Only expressed protein-coding genes and microRNAs with
p-values <0.05 were analyzed. Data represented as mean +/- SEM. P-values as indicated: *0.05, **0.01, ***0.001, and ns p>0.05. See also S3 Table.
doi:10.1371/journal.pone.0153689.g003
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Discussion
There are over 1000 different miRNAs in human cells, each with the potential to be functionally
relevant in diseases such as cancer. However, the use of large-scale loss-of-function screening to
identify functionally relevant miRNAs has been hampered by technical limitations, including the
inability of shRNAs to effectively block miRNA biogenesis and function. Most miRNAs that
have been studied to date have been assessed on an individual basis. While this has provided
important insights into the roles of those examined, many miRNAs have been left uncharacter-
ized. Consequently, there is a tremendous need for high throughput approaches to identifying
functionally relevant miRNAs in an unbiased manner to obtain a comprehensive list of miRNAs
that impact specific phenotypes. Here, we have successfully used CRISPR-Cas9 technology to
carry out a miRNA loss-of-function screen, and although further validation of individual hits is
ultimately necessary in more physiologically relevant systems, our results clearly demonstrate
that subsets of specific miRNAs act to positively or negatively control cellular proliferation and
survival in the system under study and provide a resource to guide future work.
Because miRNAs repress protein-coding target genes, data from our screen could be used to
predict functionally relevant miRNA-target gene interactions that regulate leukemic cell growth.
Using this anti-correlation functional profiling approach, we identified miRNAs with functions
that oppose a specific TSG or oncogene predicted to be a conserved target of each respective
miRNA. Further, we confirmed that miR-150 repression of p53 is a promoter of cell growth in our
system, which validates this approach. Although additional miRNA-target connections in this set-
ting require further validation, our results underscore the potential of this approach to identify
novel miRNA-target networks with relevance to cancer, and do so during a single experiment.
Our screen also identified miR-155, a miRNA that has been clinically connected to
FLT3-ITD+ AML, as a promoter of FLT3-ITD+ cell proliferation. To validate this result, we
confirmed that two independent sgRNAs against the human miR-155 hairpin sequence were
able to dramatically reduce production of mature miR-155. While one of these sgRNAs tar-
geted mature miR-155, including the seed sequence, the other targeted the loop region of the
hairpin. These results indicate that, although miRNA hairpin sequences are short, one can find
multiple CRISPR-Cas9 sites that can be used to disrupt miRNA biogenesis and subsequently
validate and study loss-of-function phenotypes.
Beyond regulating tumor cell proliferation and survival, miRNAs have been implicated in
other aspects of cancer, including drug resistance and metastasis [22, 23]. Our current
approach has the potential to be used to identify specific miRNAs and their targets that regu-
late these deleterious processes, and reveal key miRNA species that represent promising thera-
peutic targets in these contexts. Together, these approaches will provide a systematic view of
the molecular networks that coordinate malignant disease origin and subsequent outcomes
with a focus on functional relevance.
Material and Methods
Cells and tissue culture
MV4-11 cells were purchased fromATCC and used for all in vitro experimentation. Cells were cul-
tured in RPMI basedmedia supplemented with 10% FBS, and kept at 37°C with 5% CO2. Cells were
passaged every 2–3 days in order to stay within 1x105-1x106 cells/ml to maintain logarithmic growth.
CRISPR-Cas9 library screen and individual LentiCRISPRv2 infections
Genome-scale CRISPR Knock-Out (GeCKO) v2.0 was purchased from Addgene for application
in all lentiCRISPRv2 library screens, and performed as described in S1 Supporting Methods. In
MicroRNA CRISPR-Cas9 Screen in Myeloid Leukemia Cells
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brief, cells were infected, selected with puromycin, DNA was extracted, the integrated sgRNAs
were then amplified and amplicons were subjected to DNA-Seq. Single CRISPR-Cas9 vector
infections were performed using a similar approach. Unique sgRNA sequences were cloned into
a lentiCRISPRv2 construct (a gift from Feng Zhang; Addgene plasmid #52961) containing either
a puro resistance or GFP selection marker. Sequences can be found in our supplemental methods
section. The CRISPR-Cas9 library screen data have been deposited in NCBI’s Gene Expression
Omnibus under GEO: GSE71544.
Growth curves and competition assays
Growth curves using STAT5A-CR1, STAT5A-CR2, Drosha-CR1, or Ago2-CR1 cells were per-
formed in 2 ml triplicate cultures in a 6 well plate. EV infected cells were grown in parallel as a
positive control. Cells were split to 100,000 cells/ml and counted daily via microscopy using a
hemacytometer and trypan blue exclusion until cells reached ~2x106 cells/ml, or the point
when cells no longer demonstrated logarithmic growth. Competitive growth assays were per-
formed by mixing miR-155-CR1, miR-155-CR2, p53-CR1, miR-150-CR1, or EV control cells
(all GFP+) at a 1:1 ratio with WTMV4-11 cells (GFP-), and measuring the percentage of GFP
+ cells over a 4-week time course via flow cytometry.
Quantitative PCR
Total RNA was isolated fromMV4-11 cell lines and mouse BM cells using the miRNeasy spin
column kit (Qiagen). Mature miR-155 or miR-150 was quantified using the miRCURY LNA
Universal RT microRNA PCR cDNA Synthesis Kit II (Exiqon) and ExiLENT SYBR Green
master mix kit (Exiqon) on a Light Cycler 480 PCR machine (Roche). Human or mouse miR-
155 LNA primers, human miR-150 LNA primers, and 5S rRNA loading control primers were
purchased from Exiqon.
Expression profiling
Total RNA was isolated using the miRNeasy spin column kit (Qiagen). Expression of small
RNAs and long RNAs in MV4-11 cells was performed using RNA sequencing as described fur-
ther in S1 Supporting Methods. Data have been deposited into GEO as GSE71544.
Western blot analysis
Total protein extracts fromMV4-11 cell lines were harvested using RIPA lysis buffer with pro-
tease inhibitors, and protein concentration was determined using a Bio-Rad Protein Assay Dye
Reagent kit. SDS-denatured protein was separated via gel electrophoresis and transferred onto
a nitrocellulose membrane. Protein was detected via overnight antibody staining with the fol-
lowing antibodies: STAT5A (Santa Cruz L-20), Drosha (Cell Signaling D28B1), Ago2 (Cell Sig-
naling C34C6), p53 (Santa Cruz FL-393), and Actin (Sigma A5441).
Statistics
Significant p-values were determined using an unpaired Student’s t-test, unless otherwise
noted. P-values for lentiCRISPRv2 library screen were determined using DEseq2. Quantitative
data are displayed as mean +/- SEM. P-values are shown as indicated: 0.05, 0.01,
0.001, and ns p>0.05. All statistics were performed in either GraphPad Prizm6.0 or
Microsoft Excel. For calculation of p-values in growth curves, individual t-tests were performed
for the final time point.
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(PCG) pairs that regulate MV4-11 cell growth.
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